Search

Your search keyword '"Pittock, Sean J"' showing total 205 results
Start Over Author "Pittock, Sean J" Publisher lippincott williams & wilkins
205 results on '"Pittock, Sean J"'

4. Acute Optic Neuropathy in Older Adults: Differentiating Between MOGAD Optic Neuritis and Nonarteritic Anterior Ischemic Optic Neuropathy.

Author

Tisavipat, Nanthaya, Stiebel-Kalish, Hadas, Palevski, Dahlia, Bialer, Omer Y., Moss, Heather E., Chaitanuwong, Pareena, Padungkiatsagul, Tanyatuth, Henderson, Amanda D., Sotirchos, Elias S., Singh, Shonar, Salman, Abdul-Rahman, Tajfirouz, Deena A., Chodnicki, Kevin D., Pittock, Sean J., Flanagan, Eoin P., and Chen, John J.

Published
2024
Full Text
View/download PDF

5. Association of Specific “Critical” Demyelinating Lesions and Motor Impairment in Progressive Multiple Sclerosis: A Prospective Study (S46.008)

Author

Ahmad, Rowaid, primary, Jackson-Tarlton, Caitlin S., additional, Flanagan, Eoin P., additional, Messina, Steven, additional, Duffy, Dustin, additional, Tobin, W. Oliver, additional, Toledano, Michel, additional, Pittock, Sean J., additional, Lucchinetti, Claudia F., additional, Weinshenker, Brian G., additional, Kantarci, Orhun H., additional, and Keegan, B. Mark, additional

Published
2023
Full Text
View/download PDF

7. Paraneoplastic Myeloneuropathies

Author

Shah, Shailee, Vazquez Do Campo, Rocio, Kumar, Neeraj, McKeon, Andrew, Flanagan, Eoin P., Klein, Christopher, Pittock, Sean J., and Dubey, Divyanshu

Subjects
Adult, Aged, 80 and over, Male, Middle Aged, Article, HEK293 Cells, Humans, Paraneoplastic Polyneuropathy, Female, Aged, Autoantibodies, Paraneoplastic Syndromes, Nervous System, Retrospective Studies
Abstract

Objective To test the hypothesis that myeloneuropathy is a presenting phenotype of paraneoplastic neurologic syndromes we retrospectively reviewed clinical, radiologic, and serologic features of 32 patients with concomitant paraneoplastic spinal cord and peripheral nervous system involvement. Methods Observational study investigating patients with myeloneuropathy and underlying cancer or onconeural antibody seropositivity. Results Among 32 patients with paraneoplastic myeloneuropathy, 20 (63%) were women with median age 61 years (range 27–84 years). Twenty-six patients (81%) had classified onconeural antibodies (amphiphysin, n = 8; antineuronal nuclear antibody [ANNA] type 1 [anti-Hu], n = 5; collapsin response mediator protein 5 [CRMP5] [anti-CV2], n = 6; Purkinje cell cytoplasmic antibody type 1 [PCA1] [anti-Yo], n = 1; Purkinje cell cytoplasmic antibody type 2 [PCA2], n = 2; kelch-like protein 11 [KLHL11], n = 1; and combinations thereof: ANNA1/CRMP5, n = 1; ANNA1/amphiphysin, n = 1; ANNA3/CRMP5, n = 1). Cancer was confirmed in 25 cases (onconeural antibodies, n = 19; unclassified antibodies, n = 3; no antibodies, n = 3). Paraneoplastic myeloneuropathies had asymmetric paresthesias (84%), neuropathic pain (78%), subacute onset (72%), sensory ataxia (69%), bladder dysfunction (69%), and unintentional weight loss >15 pounds (63%). Neurologic examination demonstrated concomitant distal or asymmetric hyporeflexia and hyperreflexia (81%), impaired vibration and proprioception (69%), Babinski response (68%), and asymmetric weakness (66%). MRI showed longitudinally extensive (45%), tract-specific spinal cord T2 hyperintensities (39%) and lumbar nerve root enhancement (38%). Ten of 28 (36%) were unable to ambulate independently at last follow-up (median 24 months, range 5–133 months). Combined oncologic and immunologic therapy had more favorable modified Rankin Scale scores at post-treatment follow-up compared to those receiving either oncologic or immunologic therapy alone (2 [range 1–4] vs 4 [range 2–6], p < 0.001). Conclusions Paraneoplastic etiologies should be considered in the evaluation of subacute myeloneuropathies. Recognition of key characteristics of paraneoplastic myeloneuropathy may facilitate early tumor diagnosis and initiation of immunosuppressive treatment.

Published
2021

8. Tumefactive Demyelination in MOG Ab–Associated Disease, Multiple Sclerosis, and AQP-4-IgG–Positive Neuromyelitis Optica Spectrum Disorder.

Author

Cacciaguerra, Laura, Morris, Pearse, Tobin, W. Oliver, Chen, John J., Banks, Samantha A., Elsbernd, Paul, Redenbaugh, Vyanka, Tillema, Jan-Mendelt, Montini, Federico, Sechi, Elia, Lopez-Chiriboga, A. Sebastian, Zalewski, Nicholas, Guo, Yong, Rocca, Maria A., Filippi, Massimo, Pittock, Sean J., Lucchinetti, Claudia F., and Flanagan, Eoin P.

Published
2023
Full Text
View/download PDF

9. Frequency of New or Enlarging Lesions on MRI Outside of Clinical Attacks in Patients With MOG-Antibody-Associated Disease.

Author

Syc-Mazurek, Stephanie B., Chen, John J., Morris, Pearse, Sechi, Elia, Mandrekar, Jaywant, Tillema, Jan-Mendelt, Lopez-Chiriboga, A. Sebastian, Lucchinetti, Claudia Francesca, Zalewski, Nicholas, Cacciaguerra, Laura, Buciuc, Marina, Krecke, Karl N., Messina, Steven Anthony, Bhatti, M. Tariq, Pittock, Sean J., Flanagan, Eoin P., and B Syc-Mazurek, Stephanie

Published
2022
Full Text
View/download PDF

10. Comparison of 1.5 Tesla and 3.0 Tesla Magnetic Resonance Imaging in the Evaluation of Acute Demyelinating Optic Neuritis.

Author

Hur, Minjun, Madhavan, Ajay A., Hodge, David O., Eckel, Laurence J., Pittock, Sean J., Flanagan, Eoin P., Bhatti, M. Tariq, and Chen, John J.

Abstract

Background: Optic neuritis (ON) is the most common optic neuropathy in young adults. MRI is reported to have a high sensitivity for ON. Higher signal strengths of MRI may enhance resolution and lead to better detection of ON. We sought to compare the sensitivity of 3.0 Tesla (T) MRI to that of 1.5 T MRI in detecting acute demyelinating ON. Methods: A retrospective chart review was performed on patients with a clinical diagnosis of optic neuritis at Mayo Clinic Health System from January 2010 to April 2020. Among 1,850 patients identified, 126 patients met the eligibility criteria. Exclusion criteria comprised questionable or alternative diagnosis, diagnosis of ON before the study period, eye examinations performed elsewhere, or absence of fat-saturated head and orbits MRIs performed locally within 30 days of symptom onset. Gadolinium contrast enhancement, T2 hyperintensity, and the radiologic diagnosis of ON were recorded by a neuro-radiologist who was masked to the clinical history and the magnet strength of the MRI. Results: Fifty-three patients (42.1%) had 3.0 T MRI, and 73 patients (57.9%) had 1.5 T MRI. Overall, 88.9% (112/126) of patients were determined to have a positive MRI for ON. The radiographic sensitivity for ON was higher in the 3.0 T group compared with the 1.5 T group (98.1% vs 82.2%, respectively [ P = 0.004]). The frequency of gadolinium enhancement was found to be greater in the 3 T group compared with the 1.5 T group (98.1% vs 76.7%, respectively [ P < 0.001]). T2 hyperintensity was also more often seen in the 3.0 T group compared with the 1.5 T group (88.7% vs 68.5%, respectively [ P = 0.01]). Conclusions: 3.0 T MRI is more sensitive than 1.5 T MRI in detecting ON. This finding suggests that 3.0 T MRI is a preferred imaging modality for the confirmation of ON. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

13. Area postrema syndrome

Author

Shosha, Eslam, Dubey, Divyanshu, Palace, Jacqueline, Nakashima, Ichiro, Jacob, Anu, Fujihara, Kazuo, Takahashi, Toshiyuki, Whittam, Daniel, Leite, Maria Isabel, Misu, Tatsuro, Yoshiki, Takai, Messina, Silvia, Elsone, Liene, Majed, Masoud, Flanagan, Eoin, Gadoth, Avi, Huebert, Carey, Sagen, Jessica, Greenberg, Benjamin M., Levy, Michael, Banerjee, Aditya, Weinshenker, Brian, and Pittock, Sean J.

Subjects
Article
Abstract

Objective To define the frequency, duration, and severity of intractable nausea, vomiting, or hiccups in aquaporin-4–immunoglobulin G (AQP4-IgG)-positive neuromyelitis optica spectrum disorder (NMOSD) and propose diagnostic criteria and a severity scale for area postrema syndrome (APS). Methods An International NMOSD database was interrogated for frequency of APS. Patients with AQP4-IgG–positive NMOSD completed an APS symptom questionnaire. Nausea and vomiting severity was derived from the Pregnancy-Unique Quantification of Emesis and Nausea (PUQE) score. The diagnostic criteria, severity scale, and immunotherapy response was applied to a prospective validation cohort of patients from multiple centers. Results Analysis of an international database for AQP4-IgG–seropositive NMOSD (n = 430) revealed a high prevalence of isolated APS attacks (onset 7.1%–10.3%; subsequent 9.4%–14.5%) across continents. For 100 patients with 157 episodes of APS, nausea (n = 127, 81%) lasted for a median of 14 days (range 2–365), vomiting (113, 72%) with a median of 5 episodes/d (2–40) lasted 1–20 minutes, and hiccups (102, 65%) lasted a median of 14 days (2–365). Symptoms consistently and completely resolved following immunotherapy. Data were used to propose APS diagnostic criteria and repurpose PUQE score (hiccups severity grade based on symptom duration). The clinical utility was demonstrated in a prospective validation cohort. Conclusion Isolated APS attacks are frequently encountered both at onset and during the NMOSD course. The diagnostic criteria proposed here will assist clinicians in recognizing APS. Diagnosis of an APS attack earlier than 48 hours is possible if a dorsal medulla lesion is detected. Accurate diagnosis and evaluation of APS attack severity will assist in outcome measurement in NMOSD clinical trials.

Published
2018

14. Human Leukocyte Antigen Association Study Reveals DRB1*04:02 Effects Additional to DRB1*07:01 in Anti-LGI1 Encephalitis.

Author

Peris Sempere, Vicente, Muñiz-Castrillo, Sergio, Ambati, Aditya, Binks, Sophie, Pinto, Anne-Laurie, Rogemond, Veronique, Pittock, Sean J., Dubey, Divyanshu, Geschwind, Michael D., Gelfand, Jeffrey Marc, Dilwali, Sonam, Lee, Soon-Tae, Knight, Julian, Elliott, Katherine S., Irani, Sarosh, Honnorat, Jérôme, and Mignot, Emmanuel

Published
2022
Full Text
View/download PDF

18. CNS Demyelinating Attacks Requiring Ventilatory Support With Myelin Oligodendrocyte Glycoprotein or Aquaporin-4 Antibodies.

Author

Zhao-Fleming, Hannah H., Valencia Sanchez, Cristina, Sechi, Elia, Inbarasu, Jery, Wijdicks, Eelco F., Pittock, Sean J., Chen, John J., Wingerchuk, Dean M., Weinshenker, Brian G., Lopez-Chiriboga, Sebastian, Dubey, Divyanshu, Tillema, Jan-Mendelt, Toledano, Michel, Yadav, Hemang, Flanagan, Eoin P., and Sanchez, Cristina Valencia

Published
2021
Full Text
View/download PDF

19. Autoimmune gait disturbance accompanying adaptor protein-3B2-IgG.

Author

Honorat, Josephe A. MD, PhD, Lopez-Chiriboga, A. Sebastian MD, Kryzer, Thomas J. AS, Komorowski, Lars PhD, Scharf, Madeleine PhD, Hinson, Shannon R. PhD, Lennon, Vanda A. MD, PhD, Pittock, Sean J. MD, Klein, Christopher J. MD, McKeon, Andrew MD, Honorat, Josephe A, Lopez-Chiriboga, A Sebastian, Kryzer, Thomas J, Komorowski, Lars, Scharf, Madeleine, Hinson, Shannon R, Lennon, Vanda A, Pittock, Sean J, Klein, Christopher J, and McKeon, Andrew

Published
2019
Full Text
View/download PDF

20. Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder.

Author

Marignier, Romain, Bennett, Jeffrey L., Ho Jin Kim, Weinshenker, Brian G., Pittock, Sean J., Wingerchuk, Dean, Kazuko Fujihara, Paul, Friedemann, Cutter, Gary R., Green, Ari J., Aktas, Orhan, Hartung, Hans-Peter, Lublin, Fred D., Williams, Ian M., Drappa, Jorn, Dewei She, Cimbora, Daniel, Rees, William, Smith, Michael, and Ratchford, John N.

Published
2021
Full Text
View/download PDF

35. Optic Disc Edema in Glial Fibrillary Acidic Protein Autoantibody-Positive Meningoencephalitis.

Author

Chen, John J., Aksamit, Allen J., McKeon, Andrew, Pittock, Sean J., Weinshenker, Brian G., Leavitt, Jacqueline A., Morris, Padraig P., and Flanagan, Eoin P.

Abstract

Background: Glial fibrillary acidic protein (GFAP) autoantibody-positive meningoencephalitis is a newly described entity characterized by a corticosteroid-responsive meningoencephalomyelitis. Some patients with GFAP autoantibody-positive meningoencephalitis have been found to have optic disc edema, which has previously not been well characterized. Methods: We performed a retrospective, observational case series of Mayo Clinic patients found to have GFAP-IgG and optic disc edema from January 1, 2000, to December 31, 2016. We identified 40 patients with GFAP-IgG seropositivity by tissue-based immunofluorescence and cell-based assay. Patients were screened for the following inclusion criteria: 1) serum, cerebrospinal fluid, or both that yielded a characteristic astrocytic pattern of mouse tissue immunostaining with confirmation of IgG reactive with specific GFAPa isoform by cell-based assay; 2) meningoencephalitis or encephalitis; and 3) optic disc edema. We excluded those with coexisting aquaporin-4-IgG or insufficient clinical information. Results: Ten patients had optic disc edema and met inclusion criteria. The median age was 39.5 years and 60% were men. Visual acuity was unaffected and disc edema was bilateral in all cases. Mild vitreous cell was noted in 3 patients. The optic disc edema resolved with corticosteroid treatment but resulted in mild optic atrophy in 2 patients. The median lumbar puncture opening pressure was 144 mm H2O (range, 84-298 mm H2O). Brain MRI revealed radial perivascular enhancement in all except 1 patient. Fluorescein angiography was available for 1 patient with optic disc edema, which showed leakage from the venules. Conclusions: Patients with GFAP autoantibody-positive meningoencephalitis can have optic disc edema that can mimic papilledema. The cause of the optic disc edema remains uncertain, but most patients did not have raised intracranial pressure. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results